Literature DB >> 25524021

Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA patients: response to Mokuda.

K Ebina1, J Hashimoto, K Shi, M Kashii, M Hirao, H Yoshikawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25524021     DOI： 10.1007/s00198-014-2993-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  4 in total

1.  Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in rheumatoid arthritis patients.

Authors:  S Mokuda
Journal:  Osteoporos Int       Date:  2014-11-13       Impact factor: 4.507

Review 2.  The role of osteocalcin in human glucose metabolism: marker or mediator?

Authors:  Sarah L Booth; Amanda Centi; Steven R Smith; Caren Gundberg
Journal:  Nat Rev Endocrinol       Date:  2012-11-13       Impact factor: 43.330

3.  Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.

Authors:  K Ebina; J Hashimoto; K Shi; M Kashii; M Hirao; H Yoshikawa
Journal:  Osteoporos Int       Date:  2014-08-01       Impact factor: 4.507

4.  Serum undercarboxylated osteocalcin level increases with 48 weeks of teriparatide treatment in pre-treated elderly rheumatoid arthritis patients who use anti-resorptive drugs.

Authors:  S Mokuda; N Sawada; K Matoba; A Yamada; M Onishi; Y Okuda; K Jouyama; Y Murata; K Takasugi
Journal:  J Endocrinol Invest       Date:  2012-10       Impact factor: 4.256
  4 in total
  7 in total

1.  Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.

Authors:  K Ebina; T Noguchi; M Hirao; J Hashimoto; S Kaneshiro; M Yukioka; H Yoshikawa
Journal:  Osteoporos Int       Date:  2016-01       Impact factor: 4.507

2.  Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.

Authors:  K Ebina; M Hirao; J Hashimoto; H Matsuoka; T Iwahashi; R Chijimatsu; Y Etani; G Okamura; A Miyama; H Yoshikawa
Journal:  Osteoporos Int       Date:  2018-03-24       Impact factor: 4.507

3.  Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis.

Authors:  Kosuke Ebina; Masafumi Kashii; Makoto Hirao; Jun Hashimoto; Takaaki Noguchi; Kota Koizumi; Kazuma Kitaguchi; Hozo Matsuoka; Toru Iwahashi; Yasunori Tsukamoto; Hideki Yoshikawa
Journal:  J Bone Miner Metab       Date:  2016-11-09       Impact factor: 2.626

4.  The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis.

Authors:  Kosuke Ebina; Jun Hashimoto; Masafumi Kashii; Makoto Hirao; Shoichi Kaneshiro; Takaaki Noguchi; Yasunori Tsukamoto; Hideki Yoshikawa
Journal:  J Bone Miner Metab       Date:  2016-01-13       Impact factor: 2.626

5.  Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.

Authors:  Kosuke Ebina; Makoto Hirao; Jun Hashimoto; Keisuke Hagihara; Masafumi Kashii; Kazuma Kitaguchi; Hozo Matsuoka; Toru Iwahashi; Ryota Chijimatsu; Hideki Yoshikawa
Journal:  J Bone Miner Metab       Date:  2017-08-01       Impact factor: 2.626

6.  Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.

Authors:  Tomohiro Shimizu; Kosuke Arita; Eihiro Murota; Shigeto Hiratsuka; Ryo Fujita; Hotaka Ishizu; Tsuyoshi Asano; Daisuke Takahashi; Masahiko Takahata; Norimasa Iwasaki
Journal:  J Bone Miner Metab       Date:  2021-04-13       Impact factor: 2.626

7.  Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis.

Authors:  Yumejiro Nakamura; Tomohiro Shimizu; Tsuyoshi Asano; Shun Shimodan; Hotaka Ishizu; Daisuke Takahashi; Masahiko Takahata; Norimasa Iwasaki
Journal:  J Bone Miner Metab       Date:  2021-04-05       Impact factor: 2.626
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.